ribavirin has been researched along with thymalfasin in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (63.64) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shiffman, ML | 1 |
| García-Samper, X; Gongora, J; Kershenobich, D; Poo, JL; Sánchez-Avila, F; Uribe, M | 2 |
| Abbas, Z; Hamid, SS; Jafri, W; Tabassum, S | 1 |
| Abud-Bastida, F; Constantino-Casas, P; García-Contreras, F; Garduño-Espinosa, J; Nevárez-Sida, A | 1 |
| Camerini, R; Ciancio, A; DE Rosa, A; Rizzetto, M | 1 |
| Rustgi, VK | 1 |
| Sherman, KE | 1 |
| Ciancio, A; Rizzetto, M | 1 |
| Andreone, P; Bernardi, M; Cannoletta, F; Cursaro, C; Di Donato, R; Fortini, C; Gramenzi, A; Grandini, E; Loggi, E; Riili, A; Scuteri, A | 1 |
| Andreone, P; Camerini, R; Ciancio, A; De Rosa, A; Kaiser, S; Mangia, A; McBeath, R; Milella, M; Pol, S; Rizzetto, M; Solà, R; Tsianos, E | 1 |
3 review(s) available for ribavirin and thymalfasin
| Article | Year |
|---|---|
Retreatment of patients who do not respond to initial therapy for chronic hepatitis C.
Topics: Adjuvants, Immunologic; Alcoholism; Amantadine; Antiviral Agents; Black or African American; Clinical Trials as Topic; Counseling; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferons; Liver Cirrhosis; Meta-Analysis as Topic; Oligonucleotides, Antisense; Patient Compliance; Ribavirin; RNA, Viral; Thymalfasin; Thymosin; Time Factors; White People | 2004 |
Thymosin alpha 1 for treatment of hepatitis C virus: promise and proof.
Topics: Carcinoma, Hepatocellular; Chronic Disease; Clinical Trials as Topic; Hepacivirus; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Neoplasms; Randomized Controlled Trials as Topic; Ribavirin; Thymalfasin; Thymosin; Treatment Outcome | 2010 |
Thymalfasin in the treatment of hepatitis B and C.
Topics: Adjuvants, Immunologic; Antiviral Agents; Europe; Hepacivirus; Hepatitis B; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferons; Polyethylene Glycols; Polymerase Chain Reaction; Ribavirin; Thymalfasin; Thymosin; Viral Vaccines | 2010 |
2 trial(s) available for ribavirin and thymalfasin
| Article | Year |
|---|---|
Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Mexico; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Thymalfasin; Thymosin; Time Factors; Treatment Failure; Treatment Outcome; Viral Load; Virus Replication | 2004 |
Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role?
Topics: Adjuvants, Immunologic; Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thymalfasin; Thymosin; Treatment Outcome; Viral Load; Young Adult | 2012 |
6 other study(ies) available for ribavirin and thymalfasin
| Article | Year |
|---|---|
Thymosin alpha 1 in combination with interferon alpha and ribavirin in chronic hepatitis C patients who are non-responders or relapsers to interferon alpha plus ribavirin.
Topics: Adjuvants, Immunologic; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Retreatment; Ribavirin; Thymalfasin; Thymosin | 2004 |
Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study.
Topics: Adjuvants, Immunologic; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thymalfasin; Thymosin; Time Factors; Treatment Failure | 2004 |
Cost-effectiveness of chronic hepatitis C treatment with thymosin alpha-1.
Topics: Adjuvants, Immunologic; Antiviral Agents; Costs and Cost Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Mexico; Polyethylene Glycols; Prospective Studies; Quality of Life; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Thymalfasin; Thymosin | 2006 |
Studies of therapy with thymosin alpha1 in combination with pegylated interferon alpha2a and ribavirin in nonresponder patients with chronic hepatitis C.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thymalfasin; Thymosin | 2007 |
Thymalfasin for the treatment of chronic hepatitis C infection.
Topics: Adjuvants, Immunologic; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thymalfasin; Thymosin | 2007 |
Immunological modifications during treatment with thymosin alpha1 plus antiviral therapy in chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunomodulation; Male; Middle Aged; Polyethylene Glycols; Retreatment; Ribavirin; Thymalfasin; Thymosin | 2010 |